IKT (Inhibikase Therapeutics) FFO


IKT Inhibikase Therapeutics Inc IKT
36 GF Score
Price $1.87
! 1 Warning Sign
View Full Analysis

What is Inhibikase Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

IKT
36GF Score
Inhibikase Therapeutics Inc IKT
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inhibikase Therapeutics Business Description

Address 1000 N. West Street, Suite 1200, Wilmington, DE, USA, 19801
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
36GF Score

Get the complete analysis for IKT

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.87
Price